Impact of age on frailty in liver cirrhosis: a prospective cohort study
- PMID: 40514576
- PMCID: PMC12166003
- DOI: 10.1007/s10238-025-01747-3
Impact of age on frailty in liver cirrhosis: a prospective cohort study
Abstract
Frailty is an emerging predictor of adverse outcomes in liver cirrhosis, yet the interplay between aging and liver disease severity in driving frailty remains insufficiently understood. To evaluate the impact of age on the prevalence, severity, and predictors of frailty in patients with liver cirrhosis. In this prospective observational study, 460 adults with liver cirrhosis were assessed for frailty using the CFS (Clinical Frailty Scale) (CFS). Patients were classified as frail (CFS > 4) (210 cases), or non-frail (CFS ≤ 4) (250 cases). Demographic, clinical, and biochemical data of frail cases were collected. Multivariate and logistic regression analyses were performed to identify independent predictors of frailty. Frailty prevalence increased markedly with age-from 42% in patients aged 50-59 to over 90% in those aged ≥ 70. Age was moderately correlated with frailty (r = 0.40, p < 0.001). In multivariate analysis, both age (β = 0.0636, p < 0.001) and Child-Pugh score (β = 0.7874, p < 0.001) were independent predictors of frailty. Logistic regression (including interaction terms where appropriate) confirmed that each additional year of age increased frailty risk (OR = 1.13; 95% CI: 1.09-1.17, p < 0.001). Frailty in cirrhosis is strongly age-associated but also driven by hepatic dysfunction. These findings highlight the inadequacy of MELD-Na scores alone in capturing patient vulnerability, particularly in older adults. Future longitudinal studies and targeted prehabilitation strategies are warranted to mitigate frailty and improve outcomes in this vulnerable population.
Keywords: Aging; Child–Pugh score; Frailty; Liver cirrhosis; Sarcopenia.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: The study was approved by the Institutional Review Board of the National Liver Institute (IRB approval number: 0014014FWA00034015), and written informed consent was obtained from all participants prior to enrollment.
Figures
Similar articles
-
Frailty and sarcopenia in patients with cirrhosis awaiting liver transplantation: evidence from a single-centre, prospective cohort study.Updates Surg. 2024 Sep;76(5):1807-1818. doi: 10.1007/s13304-024-01962-9. Epub 2024 Aug 5. Updates Surg. 2024. PMID: 39102178
-
Sarcopenia and Frailty in Cirrhotic Patients: Evaluation of Prevalence and Risk Factors in a Single-Centre Cohort Study.Medicina (Kaunas). 2025 Apr 29;61(5):821. doi: 10.3390/medicina61050821. Medicina (Kaunas). 2025. PMID: 40428779 Free PMC article.
-
A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale.Am J Gastroenterol. 2016 Dec;111(12):1759-1767. doi: 10.1038/ajg.2016.303. Epub 2016 Aug 2. Am J Gastroenterol. 2016. PMID: 27481305
-
Frailty in advanced liver disease.Liver Int. 2018 Dec;38(12):2117-2128. doi: 10.1111/liv.13917. Epub 2018 Jul 15. Liver Int. 2018. PMID: 29935102 Review.
-
Tale of the Frail: Understanding Frailty in Cirrhosis.South Med J. 2021 Mar;114(3):186-191. doi: 10.14423/SMJ.0000000000001224. South Med J. 2021. PMID: 33655314 Review.
References
-
- Cesari M, Azzolino D. Frailty. In: Wasserman M, Bakerjian D, Linnebur S, Brangman S, Mims A, Johnson JC, eds. Geriatric Medicine. Springer; 2023. 10.1007/978-3-030-01782-8_112-1
-
- Laube R, Wang H, Park L, et al. Frailty in advanced liver disease. Liver Int. 2018;38(12):2117–28. 10.1111/liv.13917. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical